13255-23-7 Usage
General Description
The chemical "2-[4-(benzyloxy)-3-methoxyphenyl]-N-{2-[4-(benzyloxy)-3-methoxyphenyl]ethyl}acetamide" is a compound with the molecular formula C30H31NO4. It is a derivative of acetamide and contains two benzyl ether groups, two 3-methoxyphenyl groups, and an ethyl group. 2-[4-(benzyloxy)-3-methoxyphenyl]-N-{2-[4-(benzyloxy)-3-methoxyphenyl]ethyl}acetamide is a complex organic molecule with potential applications in the pharmaceutical industry due to its structural features, which may contribute to its biological activity. The presence of multiple functional groups in this chemical also makes it a versatile building block for the synthesis of various other organic compounds. However, further research is needed to fully understand the properties and potential uses of "2-[4-(benzyloxy)-3-methoxyphenyl]-N-{2-[4-(benzyloxy)-3-methoxyphenyl]ethyl}acetamide".
Check Digit Verification of cas no
The CAS Registry Mumber 13255-23-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,2,5 and 5 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 13255-23:
(7*1)+(6*3)+(5*2)+(4*5)+(3*5)+(2*2)+(1*3)=77
77 % 10 = 7
So 13255-23-7 is a valid CAS Registry Number.
13255-23-7Relevant academic research and scientific papers
TETRAHYDROPROTOBERBINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND NEURODEGENERATIVE DISEASES
-
Paragraph 0189, (2013/03/26)
Tetrahydroprotoberbine (THPB) compounds and their use in the treatment of neurological, psychiatric and neurodegenerative diseases is provided. The compounds include d-govadine, l-govadine and racemic govadine, as well as d-THPBs of general formula (I). Enantioselective processes for preparing compounds of formula (I), and d- and l-govadine are also provided.(I)
First enantioselective syntheses of the dopamine D1 and D2 receptor modulators, (+)-and (-)-govadine
Zhai, Huimin,Miller, James,Sammis, Glenn
, p. 1557 - 1559 (2012/04/04)
There is a pressing need to find and develop new antipsychotic agents for the treatment of schizophrenia. Current drugs primarily target dopamine D2receptors and are only effective in the treatment of the positive symptoms of this indication. The tetrahyd
